비교리스트

 카트 문의
시장보고서
상품코드
1425000

세계 중추신경계(CNS) 특이적 안티센스 올리고뉴클레오티드 시장 : 유형별, 용도별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 예측(2024-2032년)

CNS Specific Antisense Oligonucleotide Market, By Type, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 294 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

CNS 특이적 안티센스 올리고뉴클레오티드 시장 규모는 2023년에 51억 1,400만 달러로 2024년부터 2032년까지 연평균 복합 성장률(CAGR) 22.5%로 확대될 전망입니다.

CNS 특이적 안티센스 올리고 뉴클레오타이드 시장 - 시장 역학

중추신경계 질환의 유병률 증가가 시장 성장을 견인할 것으로 예측

CNS 특이적 안티센스 올리고뉴클레오티드는 중추 신경계 질환에 관여하는 특정 유전자 및 경로에 초점을 맞춘 정밀의료에서 표적 치료 접근법입니다. 이 방법은 광범위한 치료에 비해 더 효과적이고 안전한 치료 옵션을 제공할 잠재력을 가지고 있습니다. 최근 유엔 보고에 따르면 세계 인구의 거의 6명 중 1명에 해당하는 약 10억 명이 알츠하이머병, 파킨슨병, 뇌졸중, 다발성 경화증, 간질, 편두통, 뇌손상, 신경 감염 등의 신경 질병으로 고통받고 있습니다. 비참하게도, 이러한 질병에 의해 연간 약 680만명이 생명을 빼앗기고 있습니다. 또한 약물전달 기술의 지속적인 발전과 R&D 투자는 시장에 유망한 성장 기회를 제공합니다. 그러나 개발과 관련된 높은 비용이 시장 성장을 방해할 수 있습니다.

CNS 특이적 안티센스 올리고뉴클레오티드 시장 - 주요 인사이트력

우리 리서치 애널리스트의 분석에 따르면 세계 시장은 예측 기간(2024-2032년)에 약 22.5%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 예측됩니다.

용도별로 온라인 약국은 2023년 최대 시장 점유율을 보여줄 것으로 예측됩니다.

지역별로는 북미가 2023년 매출을 선도

CNS 특이적 안티센스 올리고뉴클레오티드 시장 - 세그먼테이션 분석 :

CNS 특이적 안티센스 올리고뉴클레오티드 세계 시장은 유형, 용도, 지역에 따라 세분화됩니다.

시장은 유형에 따라 4가지로 분류된다 : 다발성 신경염 치료제, 척수성 근위축증(SMA) 치료제, 헌팅턴병 치료제. 이러한 분류는 다양한 신경 질환을 포함하며, 중추 신경계에 특이적인 ASO는 잠재적 치료 중재 약물로 현재 연구 중입니다. 의약품 개발 상황은 빠르게 변할 수 있으며 여기에 제시된 정보는 변경될 수 있음을 인식하는 것이 중요합니다.

시장은 용도에 따라 세 가지 범주로 나뉩니다. 병원 약국, 소매 약국, 온라인 약국입니다. 시장은 주로 온라인 약국 부문에 의해 지배됩니다. 이 디지털 플랫폼은 환자가 기존 약국을 방문하지 않고 신경 질환 치료제를 포함한 처방약을 구입할 수있는 편리한 솔루션을 제공합니다.

CNS 특이적 안티센스 올리고뉴클레오티드 시장 - 지리적 통찰

CNS 특이적 안티센스 올리고뉴클레오티드 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카에 지리적으로 퍼지고 있습니다. 이 지역은 사업 활동에 관여하는 국가에 따라 추가로 분할됩니다. 시장 성장은 주로 안티센스 의약품 수요 증가와 건강 관리 지출 증가로 북미가 지배적일 것으로 예상됩니다. 북미, 특히 미국과 캐나다는 최첨단 연구시설, 임상시험 능력, 견고한 규제 체제 등 고급 의료 인프라를 보유하고 있습니다. 2021년 미국은 국내총생산(GDP)의 17.8%를 헬스케어에 지출했으며, 이는 OECD 국가의 평균의 약 2배라고 보고서 “US Health Care from a Global Perspective”에 기재되어 있습니다. 게다가, 특히 신경퇴행성 질환과 같은 과제 치료에 대한 진보된 치료 개입에 대한 수요 증가는 CNS 특이적 안티센스 올리고뉴클레오티드 요법의 채용에 유리한 환경을 생성합니다. 또한, 전달 기술의 지속적인 진보와 CNS 특이적 안티센스 올리고뉴클레오티드 요법의 세계 확대는 시장에 성장 기회를 가져올 수 있습니다. 그러나 규제 문제와 안전에 대한 우려는 시장 성장을 방해할 수 있습니다.

CNS 특이적 안티센스 올리고뉴클레오티드 시장 - 경쟁 구도 -

CNS 특이적 안티센스 올리고뉴클레오티드 시장 경쟁 구도은 생명공학 및 제약 산업에서 현저한 진전을 이루고 있습니다. 이러한 진보는 질병 관련 단백질을 표적으로 하는 혁신적인 전략에 의해 추진되어 왔습니다. 그러나 이 분야에서 신약 개발에는 시간, 노력, 자원의 상당한 투자가 필요합니다. 따라서, CNS 특이적 안티센스 올리고뉴클레오티드 시장 개척에 있어서, 각사가 이용하고 있는 기술적 플랫폼을 평가하는 것은 시장에 있어서 매우 중요합니다. 이 평가에서는 전달 방법, 표적 특이성, 신기술 등의 요소가 매우 중요한 역할을 합니다. 승인된 핵산 치료제의 수가 증가하는 것은 생체 내에서 유전자 설계도를 표적으로 함으로써 질병을 치료할 가능성을 더욱 강조합니다. 주로 단백질에 초점을 맞춘 전통적인 치료법과는 달리, 이러한 치료법은 질병의 근본 원인을 다룰 수 있다는 장점이 있습니다. 이 시장에서 주목할만한 기업은 RNA 치료제를 전문으로 하는 생명공학 기업인 Wave Life Science 입니다. 웨이브는 CNS 특이적 안티센스 올리고뉴클레오티드에 파이프라인을 특화하고 있으며, 그 기술 플랫폼과 차별화 전략을 분석하는 것이 필수적입니다.

최근 진보

2023년 10월, Biogen은 가벼운 알츠하이머병에서 타우를 표적으로 한 안티센스 올리고뉴클레오티드 치료제 BIIB080의 새로운 1b 단계 임상 데이터를 발표했습니다. 이 데이터는 뇌척수액에서 타우 단백질 수준의 감소와 다른 뇌 영역에 걸친 타우 PET(양전자 방사선 단층 촬영)의 결과를 기반으로하며 알츠하이머 병 환자의인지 기능과 일상 생활에서 유망한 동향을 보여줍니다.

목차

제1장 CNS 특이적 안티센스 올리고뉴클레오티드 시장 개요

  • 조사 범위
  • 시장 추정 연도

제2장 주요 요약

  • 시장 분석
  • 경쟁 인사이트

제3장 CNS 특이적 안티센스 올리고뉴클레오티드의 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 향후 시장 동향

제4장 CNS 특이적 안티센스 올리고뉴클레오티드 산업 연구

  • PEST 분석
  • Porter's Five Forces 분석
  • 성장 전망 맵핑
  • 규제 틀의 분석

제5장 CNS 특이적 안티센스 올리고뉴클레오티드 시장 : COVID-19의 영향 분석

  • 신형 코로나 바이러스 유행 전 영향 분석
  • 신형 코로나 바이러스 유행 후 영향 분석

제6장 CNS 특이적 안티센스 올리고뉴클레오티드 시장 상황

  • CNS 특이적 안티센스 올리고뉴클레오티드 시장 점유율 분석, 2023년
  • 주요 제조업체별 분석 데이터
    • 기존 기업의 분석
    • 신흥기업의 분석

제7장 CNS 특이적 안티센스 올리고뉴클레오티드 시장 : 유형별

  • 개요
    • 유형별 부문 점유율 분석
    • 다발성 신경장애의 치료
    • 척수성 근위축증(SMA)의 치료
    • 헌팅턴병의 치료

제8장 CNS 특이적 안티센스 올리고뉴클레오티드 시장 : 용도별

  • 개요
    • 용도별 부문 점유율 분석
    • 병원 약국
    • 소매 약국
    • 온라인 약국

제9장 CNS 특이적 안티센스 올리고뉴클레오티드 시장 : 지역별

  • 소개
  • 북미
    • 개요
    • 북미의 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽의 주요 제조업체
    • 독일
    • 이탈리아
    • 영국
    • 프랑스
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양의 주요 제조업체
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카의 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카의 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제10장 주요 벤더 분석 : CNS 특이적 안티센스 올리고뉴클레오티드 산업

  • 경쟁 대시보드
  • 기업 프로파일
    • Akcea Therapeutics, Inc.
    • Ionis Pharmaceuticals Inc.
    • Biogen Inc.
    • Sarepta Therapeutics
    • Wave Life Sciences Ltd.
    • Dynacure
    • ProQR Therapeutics NV
    • Stroke Therapeutic Inc.

제11장 애널리스트의 전방위 전망

JHS 24.02.28

REPORT HIGHLIGHT

CNS Specific Antisense Oligonucleotide Market size was valued at USD 5,114 Million in 2023, expanding at a CAGR of 22.5% from 2024 to 2032.

CNS-specific antisense oligonucleotides (ASOs) are a specific type of therapeutic agent that have been designed to target and regulate gene expression within the central nervous system. These ASOs are short, single-stranded DNA or RNA molecules that have the ability to selectively bind to complementary RNA sequences. This binding process can result in a range of cellular effects, including the degradation of the targeted RNA or the modulation of its splicing. The development of CNS-specific ASOs holds great promise for the treatment of previously challenging neurological disorders. By offering a targeted approach to modulating gene expression, these molecules have the potential to address the root causes of diseases rather than simply managing their symptoms. The FDA has already approved the use of ASOs for the treatment of ten genetic diseases, and ongoing research is exploring their potential for many more.

CNS Specific Antisense Oligonucleotide Market- Market Dynamics

Increasing Prevalence of CNS Disorders is projected to drive the growth of market

CNS-specific antisense oligonucleotides present a targeted therapeutic approach in precision medicine, focusing on specific genes or pathways implicated in CNS disorders. This method holds the potential to offer more effective and safer treatment alternatives compared to broad-spectrum treatments. According to a recent United Nations report, approximately one billion individuals, accounting for nearly one in six of the global population, suffer from neurological disorders such as Alzheimer's disease, Parkinson's disease, strokes, multiple sclerosis, epilepsy, migraines, brain injuries, and neuroinfections. Tragically, these maladies claim the lives of approximately 6.8 million people annually. Moreover, ongoing advancements in drug delivery technologies and research and development investments offer promising growth opportunities for the market. However, the high costs associated with development may impede market growth.

CNS Specific Antisense Oligonucleotide Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 22.5% over the forecast period (2024-2032)

Based on Application segmentation, Online Pharmacies was predicted to show maximum market share in the year 2023

On the basis of region, North America was the leading revenue generator in 2023

CNS Specific Antisense Oligonucleotide Market- Segmentation Analysis:

The Global CNS Specific Antisense Oligonucleotide Market is segmented on the basis of Type, Application, and Region.

The market is segmented into four classifications according to Type: Polyneuropathy Treatment, Spinal Muscular Atrophy (SMA) Treatment, and Huntington's disease Treatment. These classifications encompass various neurological conditions, and CNS-specific ASOs are currently under investigation as potential therapeutic interventions. It is crucial to acknowledge that the landscape of drug development can undergo rapid changes, and the information presented here may be subject to alteration.

The market is divided into three categories based on application: Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. The market is predominantly controlled by the Online Pharmacies segment. These digital platforms offer a convenient solution for patients to purchase prescription medications, including those used to treat neurological disorders, without the need to physically visit a traditional pharmacy.

CNS Specific Antisense Oligonucleotide Market- Geographical Insights

CNS Specific Antisense Oligonucleotide market is geographically widespread across North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided based on the countries involved in business activities. The growth of the market is expected to be dominated by North America, primarily due to the increasing demand for antisense drugs and rising healthcare expenditure. North America, particularly the United States and Canada, has advanced healthcare infrastructure, including state-of-the-art research facilities, clinical trial capabilities, and a robust regulatory framework. In 2021, the U.S. spent 17.8 percent of its gross domestic product (GDP) on healthcare, which is nearly twice the average of OECD countries, as stated in the report U.S. Health Care from a Global Perspective. Additionally, the growing demand for advanced therapeutic interventions, especially for the treatment of challenging conditions like neurodegenerative disorders, creates a favorable environment for the adoption of CNS-specific antisense oligonucleotide therapies. Furthermore, the continuous advancements in delivery technologies and the global expansion of CNS-specific antisense oligonucleotide therapies may provide growth opportunities for the market. However, regulatory challenges and safety concerns could potentially hinder the market's growth.

CNS Specific Antisense Oligonucleotide Market- Competitive Landscape:

The competitive landscape of the CNS-Specific Antisense Oligonucleotide Market has witnessed significant advancements in the biotechnology and pharmaceutical industry. These advancements have been driven by innovative strategies aimed at targeting disease-related proteins. However, the development of new drugs in this field requires a substantial investment of time, effort, and resources. Therefore, it is crucial for the market to evaluate the technological platforms utilized by different companies in the development of CNS-specific antisense oligonucleotides. Factors such as delivery methods, targeting specificity, and novel technologies play a pivotal role in this assessment. The increasing number of approved nucleic acid therapeutics further emphasizes the potential of treating diseases by targeting their genetic blueprints in vivo. Unlike conventional treatments that primarily focus on proteins, these therapeutics offer the advantage of addressing the underlying causes of diseases. One notable player in this market is Wave Life Sciences, a biotechnology company specializing in RNA therapeutics. Wave has dedicated its pipeline to CNS-specific antisense oligonucleotides, making it essential to analyze their technology platform and differentiation strategies within this context.

Recent advancements:

In October 2023, Biogen Inc. announced new Phase 1b clinical data for BIIB080, an investigational antisense oligonucleotide therapy targeting tau in mild Alzheimer's disease. The data showed promising trends in cognition and daily activities among patients with Alzheimer's disease, building upon previous results that demonstrated a reduction in tau protein levels in the cerebral spinal fluid and tau positron emission tomography across different brain regions.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Akcea Therapeutics, Inc.

Ionis Pharmaceuticals Inc.

Biogen Inc.

Sarepta Therapeutics

Wave Life Sciences Ltd.

Dynacure

ProQR Therapeutics N.V.

Stroke Therapeutic Inc.

GLOBAL CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Polyneuropathy Treatment
  • Spinal Muscular Atrophy (SMA) Treatment
  • Huntington's Disease Treatment

GLOBAL CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL CNS SPECIFIC ANTISENSE OLIGONUCLEOTIDE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. CNS Specific Antisense Oligonucleotide Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. CNS Specific Antisense Oligonucleotide Market Snippet by Type
    • 2.1.2. CNS Specific Antisense Oligonucleotide Market Snippet by Application
    • 2.1.3. CNS Specific Antisense Oligonucleotide Market Snippet by Country
    • 2.1.4. CNS Specific Antisense Oligonucleotide Market Snippet by Region
  • 2.2. Competitive Insights

3. CNS Specific Antisense Oligonucleotide Key Market Trends

  • 3.1. CNS Specific Antisense Oligonucleotide Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. CNS Specific Antisense Oligonucleotide Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. CNS Specific Antisense Oligonucleotide Market Opportunities
  • 3.4. CNS Specific Antisense Oligonucleotide Market Future Trends

4. CNS Specific Antisense Oligonucleotide Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. CNS Specific Antisense Oligonucleotide Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. CNS Specific Antisense Oligonucleotide Market Landscape

  • 6.1. CNS Specific Antisense Oligonucleotide Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. CNS Specific Antisense Oligonucleotide Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Polyneuropathy Treatment
    • 7.1.3. Spinal Muscular Atrophy (SMA) Treatment
    • 7.1.4. Huntington's Disease Treatment

8. CNS Specific Antisense Oligonucleotide Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 8.1.2. Hospital Pharmacies
    • 8.1.3. Retail Pharmacies
    • 8.1.4. Online Pharmacies

9. CNS Specific Antisense Oligonucleotide Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. CNS Specific Antisense Oligonucleotide Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. CNS Specific Antisense Oligonucleotide Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. CNS Specific Antisense Oligonucleotide Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. CNS Specific Antisense Oligonucleotide Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. CNS Specific Antisense Oligonucleotide Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- CNS Specific Antisense Oligonucleotide Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Akcea Therapeutics, Inc.
    • 10.2.2. Ionis Pharmaceuticals Inc.
    • 10.2.3. Biogen Inc.
    • 10.2.4. Sarepta Therapeutics
    • 10.2.5. Wave Life Sciences Ltd.
    • 10.2.6. Dynacure
    • 10.2.7. ProQR Therapeutics N.V.
    • 10.2.8. Stroke Therapeutic Inc.

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제